An Insulin Sensitivity Study in Healthy Subjects

ClinicalTrials.gov ID: NCT02922426

Public ClinicalTrials.gov record NCT02922426. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 3, 2026, 1:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Parallel-Group Study in Healthy Subjects to Characterize Insulin Sensitivity and Lipid Metabolism in Response to Treatment With ALKS 3831 and Olanzapine

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will characterize insulin sensitivity in response to treatment with ALKS 3831, olanzapine, and placebo.

Study identification

NCT ID: NCT02922426
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Alkermes, Inc.; Industry
Enrollment: 60 participants

Conditions and interventions

Conditions

Healthy Volunteers

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years to 40 Years
Sex: All
Healthy volunteers: Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 31, 2016
Primary completion: Jul 19, 2017
Completion: Jul 19, 2017
Last update posted: Aug 21, 2017

2016 – 2017

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Alkermes Investigational Site	Chula Vista	California	91911	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02922426, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 21, 2017 · Synced Sep 3, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02922426 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →